The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...